---
title: "Cabaletta Bio to present rese-cel pemphigus data without preconditioning at ASGCT 2026"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/284269537.md"
description: "Cabaletta Bio will present new clinical updates on rese-cel for autoimmune diseases at ASGCT 2026 in Boston from May 11-15. The presentation will include early findings from the RESET-PV trial on pemphigus vulgaris without preconditioning, initial results from two autoimmune patients treated with rese-cel via automated manufacturing, and insights on manufacturing robustness and single-cell profiling across multiple RESET Phase 1/2 cohorts."
datetime: "2026-04-27T21:00:52.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/284269537.md)
  - [en](https://longbridge.com/en/news/284269537.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/284269537.md)
---

# Cabaletta Bio to present rese-cel pemphigus data without preconditioning at ASGCT 2026

-   Cabaletta Bio scheduled new clinical and translational updates on rese-cel for autoimmune diseases at ASGCT 2026 in Boston, running May 11-15. \* Data will be presented in the future, including early findings from RESET-PV evaluating rese-cel in pemphigus vulgaris without preconditioning. \* Company will also disclose initial translational results from first two autoimmune patients treated with rese-cel produced via fully automated manufacturing using Cellares Cell Shuttle. \* Additional presentations will address manufacturing robustness across healthy donor versus patient starting material, plus single-cell profiling signals across multiple RESET Phase 1⁄2 cohorts. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cabaletta Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604271700PRIMZONEFULLFEED9707899) on April 27, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [CABA.US](https://longbridge.com/en/quote/CABA.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)

## Related News & Research

- [Sagimet Highlights Pipeline Progress and Strategic Corporate Developments](https://longbridge.com/en/news/284209078.md)
- [Intellia Therapeutics FDA Rolling Application For Gene Therapy Puts Hype To Test](https://longbridge.com/en/news/284233986.md)
- [Pharma bets a little-known form of cholesterol will underpin its next blockbuster heart drugs](https://longbridge.com/en/news/284259616.md)
- [Surrozen: Buy Rating Reiterated as Analyst Highlights Wnt-Targeted Ophthalmology Strategy and Maintains $37 Price Target](https://longbridge.com/en/news/284279788.md)
- [Carasent Buys Infosolutions, Strengthens Position In Swedish Private Healthcare](https://longbridge.com/en/news/284159872.md)